ATE486892T1 - Verfahren zur kontrolle von krebs - Google Patents
Verfahren zur kontrolle von krebsInfo
- Publication number
- ATE486892T1 ATE486892T1 AT03794710T AT03794710T ATE486892T1 AT E486892 T1 ATE486892 T1 AT E486892T1 AT 03794710 T AT03794710 T AT 03794710T AT 03794710 T AT03794710 T AT 03794710T AT E486892 T1 ATE486892 T1 AT E486892T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- provides methods
- ephb4
- controlling cancer
- cancerous growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002951409A AU2002951409A0 (en) | 2002-09-16 | 2002-09-16 | Methods for regulating cancer |
PCT/AU2003/001209 WO2004024773A1 (en) | 2002-09-16 | 2003-09-16 | Methods for regulating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE486892T1 true ATE486892T1 (de) | 2010-11-15 |
Family
ID=27792678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03794710T ATE486892T1 (de) | 2002-09-16 | 2003-09-16 | Verfahren zur kontrolle von krebs |
Country Status (15)
Country | Link |
---|---|
US (1) | US7722866B2 (de) |
EP (1) | EP1546205B1 (de) |
JP (1) | JP4799863B2 (de) |
KR (1) | KR20050072744A (de) |
CN (1) | CN1694902B (de) |
AT (1) | ATE486892T1 (de) |
AU (1) | AU2002951409A0 (de) |
BR (1) | BR0314369A (de) |
CA (1) | CA2499130A1 (de) |
DE (1) | DE60334820D1 (de) |
ES (1) | ES2355503T3 (de) |
MX (1) | MXPA05002894A (de) |
NZ (1) | NZ539203A (de) |
WO (1) | WO2004024773A1 (de) |
ZA (1) | ZA200502863B (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
JP4762889B2 (ja) | 2003-03-12 | 2011-08-31 | バスジーン セラピューティクス,インコーポレイテッド | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
EP2287194B1 (de) * | 2004-03-12 | 2016-10-26 | Vasgene Therapeutics, Inc. | EphB4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum |
DE602005025459D1 (de) * | 2004-03-12 | 2011-02-03 | Vasgene Therapeutics Inc | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum |
JP2008514925A (ja) * | 2004-09-23 | 2008-05-08 | バスジーン セラピューティクス, インコーポレイテッド | 腫瘍を検出し且つ治療するための組成物及び方法 |
US20060204512A1 (en) | 2004-09-23 | 2006-09-14 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
ZA200806053B (en) * | 2006-01-05 | 2009-12-30 | Genentech Inc | Anti-EphB4 antibodies and methods using same |
AU2013200383B2 (en) * | 2006-01-05 | 2016-05-12 | Genentech,Inc. | Anti-EphB4 antibodies and methods using same |
TWI391402B (zh) * | 2006-01-05 | 2013-04-01 | Genentech Inc | 抗ephb4抗體及使用該抗體之方法 |
SI1973950T1 (sl) | 2006-01-05 | 2015-01-30 | Genentech, Inc. | Anti-EphB4 protitelesa in postopki njihove uporabe |
NZ575918A (en) | 2006-08-31 | 2012-03-30 | A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust | Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products |
WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
AU2008226824A1 (en) * | 2007-03-12 | 2008-09-18 | Board Of Regents Of The University Of Texas System | Use of EphB4 as a diagnostic marker and a therapeutic target for ovarian cancer |
US20110009323A1 (en) * | 2007-06-15 | 2011-01-13 | Vasgene Therapeutics, Inc. | Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth |
EP2185594B1 (de) | 2007-08-13 | 2016-04-06 | VasGene Therapeutics, Inc. | Behandlung von krebs unter verwendung von humanisierten, an ephb4 bindenden antikörpern |
ES2386495T3 (es) * | 2007-11-29 | 2012-08-21 | Molecular Health Gmbh | siARN específico de EPH-B4 para reducir el crecimiento de células neoplásicas inducidas por EPO durante el tratamiento de anemia en pacientes con cáncer, receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso |
AU2015204311B2 (en) * | 2007-11-29 | 2017-06-08 | Molecular Health Gmbh | Novel tissue protective erythropoietin receptor (NEPOR) and methods of use |
US8357501B2 (en) | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
PT1135153E (pt) * | 1998-11-20 | 2005-09-30 | Genentech Inc | Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
WO2002026827A1 (en) | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
ES2372321T3 (es) * | 2001-06-20 | 2012-01-18 | Genentech, Inc. | Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón. |
JP4762889B2 (ja) * | 2003-03-12 | 2011-08-31 | バスジーン セラピューティクス,インコーポレイテッド | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
-
2002
- 2002-09-16 AU AU2002951409A patent/AU2002951409A0/en not_active Abandoned
-
2003
- 2003-09-16 CN CN038251671A patent/CN1694902B/zh not_active Expired - Fee Related
- 2003-09-16 US US10/528,029 patent/US7722866B2/en not_active Expired - Fee Related
- 2003-09-16 MX MXPA05002894A patent/MXPA05002894A/es unknown
- 2003-09-16 AT AT03794710T patent/ATE486892T1/de not_active IP Right Cessation
- 2003-09-16 ES ES03794710T patent/ES2355503T3/es not_active Expired - Lifetime
- 2003-09-16 BR BR0314369-4A patent/BR0314369A/pt active Search and Examination
- 2003-09-16 EP EP03794710A patent/EP1546205B1/de not_active Expired - Lifetime
- 2003-09-16 KR KR1020057004541A patent/KR20050072744A/ko not_active Application Discontinuation
- 2003-09-16 WO PCT/AU2003/001209 patent/WO2004024773A1/en active Application Filing
- 2003-09-16 JP JP2004534869A patent/JP4799863B2/ja not_active Expired - Fee Related
- 2003-09-16 CA CA002499130A patent/CA2499130A1/en not_active Abandoned
- 2003-09-16 NZ NZ539203A patent/NZ539203A/en not_active IP Right Cessation
- 2003-09-16 DE DE60334820T patent/DE60334820D1/de not_active Expired - Lifetime
-
2005
- 2005-04-08 ZA ZA200502863A patent/ZA200502863B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200502863B (en) | 2006-06-28 |
MXPA05002894A (es) | 2005-10-05 |
WO2004024773A1 (en) | 2004-03-25 |
NZ539203A (en) | 2008-05-30 |
DE60334820D1 (de) | 2010-12-16 |
EP1546205A4 (de) | 2006-05-03 |
KR20050072744A (ko) | 2005-07-12 |
EP1546205B1 (de) | 2010-11-03 |
AU2002951409A0 (en) | 2002-09-26 |
US20060134118A1 (en) | 2006-06-22 |
EP1546205A1 (de) | 2005-06-29 |
JP4799863B2 (ja) | 2011-10-26 |
US7722866B2 (en) | 2010-05-25 |
JP2006517906A (ja) | 2006-08-03 |
CN1694902B (zh) | 2012-10-10 |
CA2499130A1 (en) | 2004-03-25 |
BR0314369A (pt) | 2005-08-09 |
ES2355503T3 (es) | 2011-03-28 |
CN1694902A (zh) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE486892T1 (de) | Verfahren zur kontrolle von krebs | |
NO2017040I1 (no) | Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC | |
DE69233791D1 (de) | Verfahren zur Manipulation der Zelldifferenzierung | |
ATE464908T1 (de) | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern | |
BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
ATE509955T1 (de) | Humanisierte kollagen-antikörper und damit verbundene verfahren | |
RS52769B (sr) | Kompozicije i postupci za povećanje mineralizacije kostiju | |
CO5580797A2 (es) | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos | |
EA200401198A1 (ru) | АНТИТЕЛА ПРОТИВ αvβ6 | |
ATE449168T1 (de) | Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür | |
DK1325033T3 (da) | Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning | |
DE69932813D1 (de) | Nukleinsäurebindungsproteine | |
ATE505535T1 (de) | Verfahren zur herstellung stabiler b-lymphozyten | |
DE3687884D1 (de) | Monoklonale antikoerper und verfahren zum nachweis von pilzpathogenen. | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
EE200500012A (et) | Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks | |
DE602004030041D1 (de) | Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen | |
ATE206621T1 (de) | Il-8 antagonisten zur behandlung von asthma | |
DE50307968D1 (de) | Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen | |
ATE312622T1 (de) | Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin | |
DE602005025459D1 (de) | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum | |
MX2021014882A (es) | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. | |
WO2004039401A3 (en) | Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis | |
MX2023007028A (es) | Composiciones de proteínas y métodos para producir y usar las mismas. | |
MX2021014885A (es) | Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |